[{"id":"80d81649-784d-4aaa-986f-3c25d334fd80","acronym":"","url":"https://clinicaltrials.gov/study/NCT04665206","created_at":"2023-08-24T11:08:27.232Z","updated_at":"2024-07-02T16:35:04.273Z","phase":"Phase 1/2","brief_title":"Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors Enriched for Tumors With NF2 or mNF2 Gene Mutations","source_id_and_acronym":"NCT04665206","lead_sponsor":"Vivace Therapeutics, Inc","biomarkers":" NF2","pipe":" | ","alterations":" NF2 mutation","tags":["NF2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NF2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e VT3989"],"overall_status":"Recruiting","enrollment":" Enrollment 250","initiation":"Initiation: 03/24/2021","start_date":" 03/24/2021","primary_txt":" Primary completion: 12/24/2026","primary_completion_date":" 12/24/2026","study_txt":" Completion: 06/02/2027","study_completion_date":" 06/02/2027","last_update_posted":"2024-05-13"}]